Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FASN | P49327 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.49 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | GUSB | P08236 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16454839 | 0.90 | ESR1 (0.67) | MAPTESR1ESR2MEN1KMT2A | |
| SCHEMBL14904707 | 0.87 | KMT2A (0.46) | MAPTESR1ESR2MEN1KMT2A | |
| SCHEMBL18610257 | 0.82 | ESR1 (0.73) | MAPTESR1ESR2PTGS2 | |
| SCHEMBL9666436 | 0.80 | ALDH1A1 (0.65) | MAPTMEN1KMT2AL3MBTL1FASN | |
| SCHEMBL2290102 | 0.80 | MEN1 (0.58) | MAPTMEN1KMT2AFASNPTGS2 | |
| SCHEMBL2284222 | 0.80 | MAPK13 (0.54) | MAPTESR1ESR2MEN1KMT2A | |
| SCHEMBL15094561 | 0.78 | ESR1 (0.58) | MAPTESR1ESR2MEN1KMT2A | |
| SCHEMBL12905942 | 0.77 | ESR1 (0.66) | MAPTESR1ESR2PTGS2 | |
| SCHEMBL31014298 | 0.77 | FASN (0.57) | MAPTMEN1KMT2AFASNTNKS | |
| SCHEMBL15618137 | 0.77 | ALDH1A1 (0.53) | MAPTESR1ESR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170069850-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-03-09 | — | — | US | disclosed |
| US-20130105769-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130105769-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNT1, CCNE2 | MAPT 1775/4885ESR1 23/4885ESR2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.